Keys to the Cure: Will the Microbiome Live Up to the Hype?

[Available On-Demand] ・ Click video to start playback;Join chat Q&A below video
Search General Info
“The microbiome” is everywhere in the press and fast-increasing resources are devoted to it in labs worldwide. Biotechs are busy getting microbiome-modifying compounds of all kinds to the clinic while academics generate eye-watering amounts of genomic and metabolomic data.

But when will drugs and other products come out of all those efforts? The number of key phase Ib and phase II read-outs will reach an inflexion point in 2020, will pharma and the investor community adopt those projects more widely? And in the transition from lab to clinic to drug-on-market, can this new frontier learn from those who have gone before? Panelists will address these questions and more.
Moderator
photo
General Assignment Reporter
STAT News
Speakers
photo
Chief Scientific Officer
Rebiotix
photo
CEO and Managing Partner
Seventure
photo
CEO and Co-Founder
Siolta Therapeutics
photo
CEO
LNC Therapeutics
photo
CEO
Bacthera AG
photo
General Assignment Reporter
STAT News